NDLI: Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies.

Please wait, while we are loading the content...

Relationships between changes in sustained fronto-striatal connectivity and positive affect in major depression resulting from antidepressant treatment.

Association between older age and more successful aging: critical role of resilience and depression.

Parity: an ongoing challenge and research opportunity.

Clozapine's role in the treatment of first-episode schizophrenia.

Evidence for a genetic component for substance dependence in Native Americans.

The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation.

Prevalence, comorbidity, and correlates of DSM-5 proposed disruptive mood dysregulation disorder.

The effects of mental health parity on spending and utilization for bipolar, major depression, and adjustment disorders.

Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies.

Does a quality improvement intervention for anxiety result in differential outcomes for lower-income patients?

Year: 2013 Volume: 170 Issue: 1

Year: 2012 Volume: 169

Year: 2011 Volume: 168

Year: 2010 Volume: 167

Year: 2009 Volume: 166

Year: 2008 Volume: 165

Year: 2007 Volume: 164

Year: 2006 Volume: 163

Year: 2005 Volume: 162

Year: 2004 Volume: 161

Year: 2003 Volume: 160

Year: 2002 Volume: 159

Year: 2001 Volume: 158

Year: 2000 Volume: 157

Year: 1999 Volume: 156

Year: 1998 Volume: 155

Year: 1997 Volume: 154

Year: 1995 Volume: 152

Year: 1994 Volume: 151

Year: 1985 Volume: 142

Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Spatial Coverage	Europe
Abstract	OBJECTIVE: Indirect evidence suggests that common genetic variation contributes to individual differences in antidepressant efficacy among individuals with major depressive disorder, but previous studies may have been underpowered to detect these effects. METHOD: A meta-analysis was performed on data from three genome-wide pharmacogenetic studies (the Genome-Based Therapeutic Drugs for Depression [GENDEP] project, the Munich Antidepressant Response Signature [MARS] project, and the Sequenced Treatment Alternatives to Relieve Depression [STARD] study), which included 2,256 individuals of Northern European descent with major depressive disorder, and antidepressant treatment outcomes were prospectively collected. After imputation, 1.2 million single-nucleotide polymorphisms were tested, capturing common variation for association with symptomatic improvement and remission after up to 12 weeks of antidepressant treatment. RESULTS: No individual association met a genome-wide threshold for statistical significance in the primary analyses. A polygenic score derived from a meta-analysis of GENDEP and MARS participants accounted for up to approximately 1.2% of the variance in outcomes in STARD, suggesting a weakly concordant signal distributed over many polymorphisms. An analysis restricted to 1,354 individuals treated with citalopram (STAR*D) or escitalopram (GENDEP) identified an intergenic region on chromosome 5 associated with early improvement after 2 weeks of treatment. CONCLUSIONS: Despite increased statistical power accorded by meta-analysis, the authors identified no reliable predictors of antidepressant treatment outcome, although they did identify modest, direct evidence that common genetic variation contributes to individual differences in antidepressant response.
File Format	HTM / HTML
ISSN	0002953X
e-ISSN	15357228
Journal	American Journal of Psychiatry
Issue Number	2
Volume Number	170
Language	English
Publisher	American Psychiatric Association
Publisher Date	2013-02-01
Publisher Place	United States
Access Restriction	Open
Subject Keyword	Discipline Psychiatry Citalopram Depressive Disorder, Major Pharmacogenetics Antidepressive Agents, Second-generation Administration & Dosage Pharmacokinetics Chromosomes, Human, Pair 5 Diagnosis Drug Therapy Epidemiology Genetics Genetic Variation Genome-wide Association Study Polymorphism, Single Nucleotide Psychiatric Status Rating Scales Remission Induction Meta-analysis Research Support, N.i.h., Extramural Research Support, Non-u.s. Gov't
Content Type	Text
Resource Type	Article
Subject	Psychiatry and Mental Health

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Genome-wide pharmacogenetics of antidepressant response in the GENDEP project.

Meta-analysis of Genome-wide Association Studies for Neuroticism, and the Polygenic Association With Major Depressive Disorder

Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder.

HTR2A gene variation is involved in antidepressant treatment response.

Common genetic variation in the indoleamine-2,3-dioxygenase genes and antidepressant treatment outcome in major depressive disorder.

Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment.

Genome-wide linkage and follow-up association study of postpartum mood symptoms.

From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment.

Antidepressant pharmacogenetics.

Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies.

Similar Documents

Genome-wide pharmacogenetics of antidepressant response in the GENDEP project.

Meta-analysis of Genome-wide Association Studies for Neuroticism, and the Polygenic Association With Major Depressive Disorder

Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder.

HTR2A gene variation is involved in antidepressant treatment response.

Common genetic variation in the indoleamine-2,3-dioxygenase genes and antidepressant treatment outcome in major depressive disorder.

Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment.

Genome-wide linkage and follow-up association study of postpartum mood symptoms.

From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment.

Antidepressant pharmacogenetics.

Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies.